In addition, BRAF/MEK inhibitors-induced reactivation of MAP kinase signaling by the enhancement of BRAFV600E amplification or alternative splicing, RAS-mutation can also contribute to the development of tumor plasticity [10,16]. The gene discussed is MAP2K7; the disease is neoplasm.